TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03828383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-home technology
Description: Intelligent bots monitor the in-home sensors, learn typical patterns, and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome behaviors occur. Social contact is encouraged using a trusted circle of friends and family who are encouraged to stay in contact and share photos and videos with the caregiver and person with dementia via the digital display.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Limited in-home technology
Description: Intelligent bot monitors the in-home water leak sensor and provide caregivers with text messages via cell phone and alerts via the tablet when worrisome conditions occur.
Study: NCT00540267

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT00308685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albuterol
Description: Albuterol 90mcg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00683384

Intervention type: DRUG
Intervention: Etanercept (Enbrel)
Study: NCT01456338

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for PTSD
Description: Individual CBT, approx. 12 sessions, one session per week

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Individual Addiction Counseling
Description: Individual therapy, approx. 12 sessions, one session per week
Study: NCT04503200

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Double guidewire
Description: After the 3rd passage of the guidewire into the pancreatic duct, the catheter will be removed leaving the guidewire in place. The catheter will be re-inserted and a second guidewire will be used and directed above the pancreatic wire in the 11-12 o'clock direction to attempt cannulation of the common bile duct.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transpancreatic precut
Description: After the 3rd passage of the guidewire unintentionally into the pancreatic duct, the guidewire will be left in the pancreatic duct, a sphincterotome will be used to cut in the direction of 11-12 o'clock attempting to deroof the pancreatic duct and gain access into the common bile duct. The wire will then be retracted and reinserted in the direction of the cut to attempt cannulation of the common bile duct.
Study: NCT00922389

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: will receive G-CSF and peripheral blood derived mononuclear cells
Description: Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.

Intervention type: DRUG
Group type: OTHER
Intervention: G-CSF
Description: 5 micrograms/kg/day for 4 days by subcutaneous route

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
Study: NCT02819375

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: 1 mg/kg propofol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol+Remifentanil
Description: 0.5 mg/kg propofol+0.5 mg/kg remifentanil

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol+Ketamine
Description: 0.5 mg/kg propofol and 0.5 mg/kg ketamine
Study: NCT01053052

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sonography with FemVue, and HSG
Description: Sono HSG for FDA 510(k) cleared indication for use
Study: NCT01957800

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website
Description: Website will have action planning with social interactions and support features for sharing, reusing, and recommending strategies for improving habits.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Participants will record their weight and complete surveys online.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Participants will record their weight and complete surveys online.
Study: NCT00809146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular route of active treatment
Description: IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous route of active treatment
Description: IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
Study: NCT03158311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149
Description: Indacaterol acetate / glycopyrronium bromide / mometasone furoate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QVM149
Description: Indacaterol acetate / glycopyrronium bromide / mometasone furoate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Salmeterol/fluticasone plus tiotropium
Description: Free triple arm of salmeterol / fluticasone plus tiotropium
Study: NCT01746160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C1 Implant
Description: Patients treated with dental implants.
Study: NCT01018953

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIM 23A760
Description: BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
Study: NCT02127515

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non Invasive Prenatal Testing
Study: NCT04302025

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Participants will receive surgical resection of the primary tumor along with selected lymph nodes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Participants will receive surgical resection of the primary tumor along with selected lymph nodes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Participants will receive standard of care (SOC) chemotherapy as determined by the treating physician

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divarasib
Description: Participants in the KRAS G12C cohort will receive divarasib for approximately 8 weeks until the day before surgery.
Study: NCT03727061

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Immunotherapy - Standard of care

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Porfimer Sodium
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Interstitial Illumination Photodynamic Therapy
Description: Undergo I-PDT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality of Life Assessment
Description: Ancillary Studies
Study: NCT02127515

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Invasive Prenatal Testing
Study: NCT04899128

Intervention type: DRUG
Intervention: Pyrotinib
Description: Pyrotinib-based therapy
Study: NCT02857959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzathine Penicillin G

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Benzathine Penicillin G
Study: NCT03255174

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVARREST® Fibrin Sealant Patch
Description: EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts- a flexible matrix and a coating of biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
Study: NCT02790489

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Valedia
Study: NCT02679703

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular transcutaneous electrical stimulation (TENS)
Description: Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Group
Description: The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
Study: NCT00834340

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glimepiride 4 mg Tablets
Description: 1 x 4 mg, single-dose fasting
Study: NCT03091023

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial Biopsy and endometrial fluid collection
Study: NCT00834340

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AMARYL® 4 mg Tablets
Description: 1 x 4 mg, single-dose fasting
Study: NCT01205009

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovitrelle
Description: One dose of Ovitrelle 250 mcg
Study: NCT04402502

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound Imaging
Description: The participant will go to the Rheumatology clinic (St. Joseph's Hospital) and have 3D hand ultrasound performed on their hands.
Study: NCT01146925

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRMD-001-Deferiprone
Description: CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
Study: NCT03643692

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ARISES
Description: The Adaptive, Real-time, Intelligent System to Enhance Self-care of chronic diseases (ARISES) project will use type 1 diabetes (T1DM) as an exemplary case study to demonstrate safety, technical proof of concept and efficacy of a novel mobile platform. Combining wearable sensors and smartphone technology, a range of biological, environmental and behavioural data will be analysed to provide real-time therapeutic and lifestyle decision support. Using Case-Based-Reasoning (CBR), the system will be adaptive and personalised with the ability to learn from previously encountered scenarios. Ultimately, ARISES aims to empower self-management of chronic illness and limit the complications associated suboptimal treatment.
Study: NCT00246259

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone long-acting injection (LAI)
Description: Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Antipsychotic
Description: Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
Study: NCT05971797

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REBT
Description: During REBT in patients with osteoarthritis and concomitant diseases with diagnosed depression or anxiety before arthroplasty the patients learn how to manage their irrational or unhealthy emotions, thoughts, and behaviors.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: REBT
Description: During REBT in patients with osteoarthritis and concomitant diseases with diagnosed depression or anxiety before arthroplasty the patients learn how to manage their irrational or unhealthy emotions, thoughts, and behaviors.
Study: NCT04193683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Myofascial Release Technique
Description: Myofascial release technique will bi applied bottom of the feet, back of the legs and hamstrings in both extremities. The practitioner will decide how long she should stay in a region according to the feeling of releasing in the tissue. The technique will be applied to a region at least 3 times.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham-Ultrasound
Description: Sham-ultrasound will be applied to back of legs and thighs in both extremities without pressure and all parameters of the ultrasound device except the timer will be closed.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham-Ultrasound
Description: Sham-ultrasound will be applied to back of legs and thighs in both extremities without pressure and all parameters of the ultrasound device except the timer will be closed.
Study: NCT02495779

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: emtricitabine/tenofovir
Description: Short-term episodic use for 2-3 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT-based counseling
Description: Brief CBT-based counseling to promote adherence
Study: NCT02534649

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Newly obtained biopsy and Blood samples collection
Description: For each patient:~* Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling~* Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.~Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.~All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report.
Study: NCT03301857

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Denosumab
Description: 120 mg administered subcutaneously (SC) every 4 weeks (Q4W).
Study: NCT02913989

Intervention type: OTHER
Intervention: Smoking habits characterization

Intervention type: OTHER
Intervention: Smoking habits characterization
Study: NCT02655484

Intervention type: DEVICE
Group type: OTHER
Intervention: BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）
Description: See details from arm descriptions.
Study: NCT03253003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Line extension of the Phonak Audéo B product family
Description: The line extension of Phonak Audéo B product family will be fitted to the participants individual hearing loss.
Study: NCT02286739

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TKA with Verasense
Description: VERASENSE replaces the standard tibial trial inserts and is embedded with microelectronics and sensors to provide surgeons with real-time knee kinetic data. The data is wirelessly transmitted to a graphic display (VERASENSE Knee Application), allowing surgeons to quantify and assess soft tissue intercompartmental loads throughout the range of motion. The VERASENSE sensor is not an investigational device. OrthoSensor, Inc., received FDA pre-market submission (510K) clearance in 2009. The indication for use is a tool for adjustment of the femoral knee implant to reduce instability from flexion gap asymmetry. The VERASENSE sensor is sterile and single patient use.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: TKA without Verasense
Description: TKA will be performed manually without the use of Verasense
Study: NCT03979508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgical resection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: Undergo standard of care surgical resection
Study: NCT04574219

Intervention type: OTHER
Group type: OTHER
Intervention: Use of Facetime with child and parents during induction
Description: Families will be able to use Facetime with their child when the child is taken to the operating room

Intervention type: OTHER
Group type: OTHER
Intervention: Use of Facetime with child and parents during induction
Description: Families will be able to use Facetime with their child when the child is taken to the operating room

Intervention type: OTHER
Group type: OTHER
Intervention: Use of Facetime with child and parents during induction
Description: Families will be able to use Facetime with their child when the child is taken to the operating room
Study: NCT01866670

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: spiritual support
Description: -Spiritual Support: deep breathing + guided image + meditation
Study: NCT01726361

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidimensional Treatment Foster Care
Description: Out of home placement in MTFC family for 10-12 months

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: Other kinds of out of home placement
Study: NCT03328819

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The following depression-specific acupoints: Baihui (Du-20), Yintang (EX-HN3), Sishencong (EX-HN1), bilateral Cuanzhu (BL2), bilateral Toulinqi (GB15), bilateral Neiguan (PC6), bilateral Shenmen (HT7), bilateral Sanyinjiao (SP6), and bilateral Taichong (LR3). These depression-specific acupoints could raise up the qi, calm the mind, smooth liver qi stagnation, promote blood circulation, remove blood stasis, and nourish yin. The following pain-specific acupoints: bilateral Fengchi (GB20), bilateral Jianjing (GB21), bilateral Quchi (LI11), bilateral Shousanli (LI10), bilateral Hegu (LI4), bilateral Wangu (SI4), bilateral Shenshu (BL23), bilateral Huantiao (GB30), bilateral Weizhong (BL40), bilateral Feiyang (BL58), bilateral Yanglingquan (GB34), bilateral Yinlingquan (SP9), and bilateral Taixi (KI3). These pain-specific acupoints could eliminate wind, relax muscles, promote blood circulation, and supplement the kidney.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: The following depression-specific acupoints: Baihui (Du-20), Yintang (EX-HN3), Sishencong (EX-HN1), bilateral Cuanzhu (BL2), bilateral Toulinqi (GB15), bilateral Neiguan (PC6), bilateral Shenmen (HT7), bilateral Sanyinjiao (SP6), and bilateral Taichong (LR3). These depression-specific acupoints could raise up the qi, calm the mind, smooth liver qi stagnation, promote blood circulation, remove blood stasis, and nourish yin. The following pain-specific acupoints: bilateral Fengchi (GB20), bilateral Jianjing (GB21), bilateral Quchi (LI11), bilateral Shousanli (LI10), bilateral Hegu (LI4), bilateral Wangu (SI4), bilateral Shenshu (BL23), bilateral Huantiao (GB30), bilateral Weizhong (BL40), bilateral Feiyang (BL58), bilateral Yanglingquan (GB34), bilateral Yinlingquan (SP9), and bilateral Taixi (KI3). These pain-specific acupoints could eliminate wind, relax muscles, promote blood circulation, and supplement the kidney.
Study: NCT01397019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin, irinotecan, 5-FU & leucovorin
Description: FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
Study: NCT01122329

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: caprylidene
Description: Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03419793

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: segmental vibration device
Description: segmental vibration device

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: physical therapy exercises

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical therapy exercises
Study: NCT01014884

Intervention type: OTHER
Group type: OTHER
Intervention: Multidisciplinary team interventions
Description: The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.

Intervention type: OTHER
Group type: OTHER
Intervention: Multidisciplinary team bimonthly visits either in person or via telephone.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager
Study: NCT01605474

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient discharged home after foley bulb placement.
Description: The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.

Intervention type: OTHER
Group type: NO_INTERVENTION
Intervention: Inpatient
Description: The patients will not be discharged home after assessment and placement of the foley catheter.
Study: NCT02186392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Circadian Light luminaries
Description: The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
Study: NCT04241029

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: IDOFORM®Travel
Description: Four capsules IDOFORM®Travel orally every 24 hour (12\*10\^9 cfu/day) for eight weeks.
Study: NCT03731793

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Non-Animal Chondroitin Sulphate
Description: Mythocondro® is an ichthyic-like chondroitin sulfate produced by chemical sulfation of a non-sulfated chondroitin backbone obtained by thermo-acid hydrolysis of the capsular polysaccharide naturally produced by an Escherichia coli strain.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01574573

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self support, group sessions
Description: Self support,group sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self support, group sessions
Description: Self support,group sessions